Press release
May 14, 2019

Sosei Heptares reports progress with Pfizer as multi-target collaboration delivers first candidate for clinical advancement

Tokyo, Japan and London, UK, 14 May 2019 – Sosei Group Corporation (“the Company”; TSE: 4565) reports encouraging progress and initial success of its strategic multi-target drug discovery collaboration with Pfizer. The research phase of the collaboration has delivered several milestones leading to the advancement of new potential candidate programs against G protein-coupled receptor (GPCR) targets nominated by Pfizer in major disease areas.

These targets have clinical and biological validation as key points for therapeutic intervention targeting metabolic and inflammatory diseases but have proved challenging to address with conventional discovery approaches because of inherent technical challenges.  To address   these challenges, Sosei Heptares and Pfizer scientists have worked closely together to leverage their complementary expertise in enabling GPCR-focused structure-based drug design (SBDD) and development initially directed towards up to ten GPCR targets nominated by Pfizer.

In addressing these targets, Sosei Heptares has delivered stabilized receptors (StaR® proteins), X-ray structures and biophysical data on certain programs, triggering milestone payments from Pfizer, including US$3 million announced today. Further milestones payments are contemplated under the agreement, with potential for royalties also payable provided the criteria under the agreement are satisfied. Pfizer also made a US$33 million equity investment in Sosei Heptares in 2015. In the future, Pfizer and Sosei Heptares anticipate publication of select research findings from their collaboration.

Dr. Malcolm Weir, Executive VP and Chief R&D Officer of Sosei Heptares, said: “Pfizer has a real appreciation of the potential value that structural studies can bring to drug design and discovery. Sosei Heptares is delighted with the relationship and interaction that has developed between our respective scientists since starting the collaboration and particularly with the achievement announced today. This was made possible, in part, through the collaborative application of our SBDD platform, which is also being used in other promising programs. We look forward in the coming years to the continued progress of these programs."

Charlotte Allerton, Head of Medicine Design at Pfizer said: "We are very pleased with the progress achieved through our collaboration with Sosei Heptares and are optimistic about our future work together. Sosei Heptares’ GPCR-focused structure-based drug design provides us with a valuable new approach to potentially enable the design of small molecules to modulate important disease targets."


–        ENDS    –